{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000030","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.265050+00:00","generated_at":"2026-06-17T07:07:52.846057+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Gossamer Bio discontinues GB5121 after FDA partial clinical hold; SAEs included fatal hemorrhage","bullets":["FDA placed partial clinical hold on all GB5121 trials after atrial fibrillation, sudden death, and fatal intracranial hemorrhage in STAR-CNS study.","Company terminated all ongoing GB5121 studies and discontinued development of the drug.","Enrollment had been paused March 17, 2023, based on benefit/risk and to prioritize seralutinib program.","No other pipeline updates disclosed; seralutinib remains the priority program."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000030","json":"https://secwatch.observer/filing/0001728117-23-000030.json","markdown":"https://secwatch.observer/filing/0001728117-23-000030.md","text":"https://secwatch.observer/filing/0001728117-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000030/0001728117-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000030/goss-20230403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:07:52.846057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}